Monday, September 22, 2008

Event: Esprit Entrepreneur and CU Technology Transfer Office Present CU Innovation Alliance Breakfast

(LINK)

BOULDER, Colo. (September 22, 2008) - The Boulder Chamber of Commerce’s annual Esprit Entrepreneur will offer the CU Innovation Alliance Breakfast on October 1st, 8:00-9:30 a.m. at the Millennium Harvest House Hotel. This breakfast, in conjunction with the 24th annual Esprit Entrepreneur Event, will highlight emerging CU-Boulder technologies at all stages – in the lab, new startup companies and successful businesses. “It is a great opportunity to meet the players in CU’s technology community and see upcoming technology and entrepreneurs,” states Mark Weakley of Holme Roberts and Owen, sponsor of the breakfast.

Technology and companies presenting include:

Suvica will use a novel technology platform developed at CU-Boulder that recreates tissue microenvironment to discover new anti-cancer agents that work in combination therapy and target cancerous tissues preferentially over normal tissue.

Colorado Carbon Capture (update: now Ion Engineering) focuses on improving the efficiency of carbon capture from power plants and natural gas wells.

TissueFusion, LLC is building laser devices to “weld” biological tissues together for wound closures.

LineRate Systems is rethinking multi-gigabit network appliance platforms to provide multi-gigabit application performance, increased flexibility, reduced time to market, and continuously decreasing cost.

3QMatrix, Inc. focuses on the development and commercialization of novel wound healing and drug delivery products using a proprietary product platform.

XenoPur Systems, Inc. is commercializing a CU-Boulder technology, the CARBONATOR, which provides metals decontamination, a substantial part of the water treatment process.

KMLabs Inc. is a leading manufacturer of ultra-short pulse lasers for the research market. Their 20-person team includes several of the world’s most renowned experts in laser technology.

Register for the CU Alliance Technology Breakfast and other Esprit events at http://www.esprit2008.com/.

Podcast: Colorado Economic Development Stimulated by Tech Transfer and Bioscience

HB-08 1001, signed into law in April 2008, gives a five year pipeline of new Colorado bioscience companies, potentially generating hundreds of new jobs in the industry as well as increased private capital invested in Colorado companies. For part 2 of this series on the bill, Larry Nelson of w3w3.com interviewed three key players in this new initiative: David Allen, Associate Vice President Tech Transfer Office at the University of Colorado (CU TTO); Denise Brown, Executive Director of the Colorado BioScience Association (CBSA); and Richard Duke, Chair of CBSA’s Public Policy and Government Relations Committee, as well as President and CEO of Apoplogic Pharmaceuticals.

Listen to the podcast.

Wednesday, September 17, 2008

September 2008 Newsletter Now Available

Highlights from TTO's September 2008 newsletter:

Zenwa to Commercialize CU Optics Technology
Massachusetts-based Zenwa Inc. recently executed an exclusive license with CU TTO for a patented polymer waveguide array technology developed by Assistant Professor Robert McLeod in the Department of Electrical and Computer Engineering at CU-Boulder. Zenwa has received a $500K grant to develop the CU technology for use in endoscopy, and will also use the technology to develop medical devices for improved vision.

TTO To Host ESPRIT Innovation Alliance Breakfast
As part of the Boulder Chamber of Commerce ESPRIT Entrepreneur week, TTO will again host this event showcasing CU innovations at all stages of development, from lab to startup to successful company. Following these short presentations, there will be an opportunity to mingle with the researchers and entrepreneurs, as well as with TTO staff and other members of the CU innovation community. More events, details and registration at the Esprit Entrepreneur 2008 website.

TTO Accepting Proposals for Proof of Concept Investment Fall Round
The application deadline for the fall TTO Proof of Concept investment (POCi) round is Friday, October 10, 2008. The POCi program provides early-stage "seed" investments of $100,000 to enable the further development and validation of promising CU technologies that are, or will become, the platform for a CU start-up company. Information about the POCi program, selection criteria, application requirements, and the application form are available online; for questions about the POCi program, contact Tom Smerdon, Director of Licensing and New Business Development, 303-735-0621.

TTO Announces Deadline for Colorado Bioscience Research Grants
The deadline to apply for a Colorado Bioscience Research Grant will be Friday, October 17, 2008. This statewide program was signed into law in April 2008, and provides $26.5M over five years to grow Colorado's bioscience industry. University researchers are eligible for awards of $50,000 to $200,000 for commercial proof-of-concept work; eligible fields include therapeutics, diagnostics, medical devices, platform technologies, and biofuels. Applications and more information are available online - for questions, please contact Rick Silva, 303-724-0222 (UC-Denver) or Kate Tallman, 303-492-5732 (CU-Boulder and CU-Colorado Springs). Important: invention disclosures must be submitted to TTO by Monday, September 22 to qualify.

TTO Accepting Proposals for Renewable Energy Proof of Concept Grants
The CU TTO has set aside $200,000 to support Proof of Concept grants (POCg) of up to $50,000 to support the further development and validation of promising CU-Boulder renewable energy technologies. Proposals are sought in all areas related to the development of renewable and sustainable energy sources as well as efficient utilization of energy. The fall application deadline is Friday, October 24. Information about the Renewable Energy POCg program, selection criteria, application requirements, and the application form are available online; for questions, contact Kate Tallman, 303-492-5732.

Reminder: Deadline for State Matching Funds for Early Stage Bioscience Companies
The Early-Stage Bioscience Company Grant Program is one of the funding initiatives in the HB 1001 legislation, and is intended to accelerate the commercialization by Colorado start-up companies of bioscience technologies developed at research institutions in Colorado. The program provides for a 1:1 match of eligible company funds, up to a total grant amount of $250,000. To be eligible for a grant, a company must be an Early-Stage Bioscience Company as defined in the OEDIT Program Rules, have a license to commercialize bioscience technology from a Colorado research institution, and have secured at least a 1:1 match of the grant amount requested, sourced from other grants or third party investors. More information is available online, including a link to the Rules and Application and accompanying forms. The deadline for this round is Sunday, November 30.

Read the full newsletter.

Wednesday, September 10, 2008

Press Release: Zenwa to Commercialize Univ. of Colorado Optics Technology

Zenwa, Inc. has received a $500K grant to develop the CU technology for use in endoscopy, and will also use the technology to develop medical devices for improved vision. (LINK)

BOULDER, Colo. (September 10, 2008) - Massachusetts-based Zenwa Incorporated recently executed an exclusive license with the University of Colorado for a patented polymer waveguide array technology developed by Assistant Professor Robert McLeod in the Department of Electrical and Computer Engineering at CU-Boulder.

The license agreement with the University of Colorado’s Technology Transfer Office (TTO) and Zenwa supports a technology that would produce better techniques for the aid and rehabilitation of the legally blind and partially sighted, among other applications. The planned first product of the polymer waveguide array technology is for a family of disposable endoscope probes; to replace multi-use fiber bundle technology based devices. In support of the endoscope development initiative, Zenwa has received a Phase 2 Small Business Technology Transfer (STTR) grant from the NSF the amount of $500,000 for a 24-month program that started in August of 2008.

Another planned early application includes a multi-functional low vision eye research platform that will be used for clinical research to develop new diagnostic procedures and treatments, as well as for low vision engineering research to produce further aid and rehabilitation for individuals considered legally blind or partially sighted. The system will have the capability to track the eyes, image the retina and present a visual stimulus with a single, affordable device. The license is in the field of use that includes Zenwa’s newest patent-pending product, a generic ocular platform incorporated into the form factor of a personal eyeglass-mounted display with stereo and 3-D capabilities.